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Edited by Shou-Wei DingAbstract A virus-associated RNA (VAI) of adenoviruses is a
cytoplasmic non-coding RNA and it plays an important role
for viral replication in infected cells. VAI RNA transcripts, pro-
duced by RNA polymerase III (pol III), form tightly structured
stems, which confer resistance to cellular defense systems. We
demonstrate here that small RNAs of approximately 22 nucleo-
tides are produced from a terminal stem region but not from an
apical stem of VAI RNA. We determined the processing sites of
VAI RNA by S1 nuclease mapping and further conﬁrmed that
the processed small RNA can act as small interfering RNAs
(siRNAs) or as microRNAs (miRNAs) in transient transfection
assays and during viral infection. Our data demonstrate that
non-coding RNAs synthesized by pol III can be substrates for
Dicer, and diced small RNAs might regulate cellular phenomena
as siRNAs and miRNAs.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Adenovirus; VAI RNA; Dicer; SiRNA; MiRNA1. Introduction
The genome of adenovirus type 2 encodes two non-coding
RNAs, VAI and VAII [1]. VAI RNA is synthesized by RNA
polymerase III (pol III) and accumulated in large amounts late
in the course of infection, and it plays an important role for
viral replication in infected cells [2,3]. VAI RNA acts as a po-
sitive regulator for the neutralization of an interferon-related
cellular defense mechanism [4,5]. During adenoviral infection,
the double-stranded RNA-induced protein kinase (PKR) is
activated at late stages, probably by the production of long
double-stranded RNAs through the symmetrical transcription
of the viral genome [6]. Then, the activated PKR phosphory-
lates the eukaryotic translational initiation factor 2 (eIF2a),
leading to the inhibition of whole protein synthesis [4,5].
VAI RNA binds to and blocks the activation of PKR, thereby
preventing the PKR-mediated inhibition of the protein synthe-
sis [4–8]. VAI RNA forms tightly structured stems, which serve
as the binding site for PKR proteins. The secondary structure
of VAI RNA includes two short imperfectly base-paired stems,
referred to as the terminal and apical stems, respectively, and a*Corresponding author. Fax: +81 29 861 3019.
E-mail address: y-kato@aist.go.jp (K. Taira).
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doi:10.1016/j.febslet.2006.01.085structurally complex domain, known as the central domain
[9,10] (Fig. 1A).
Recently, it has been recognized that animal and plant gen-
omes contain an abundance of small regulatory RNAs of
approximately 22 nucleotides (nts) in length [11–17]. One class
of small RNAs called microRNAs (miRNAs) has a variety of
functions and is involved in the regulation of gene expression
[18–26]. So far, many studies revealed the key roles of miRNAs
in diverse regulatory pathways, including developmental tim-
ing control, apoptosis, organ development and cell diﬀerentia-
tion. miRNAs generally repress mRNA translation by
partially base-paring to the 3 0-untranslated region (UTR) of
target mRNAs.
In addition to miRNAs, small interfering RNAs (siRNAs)
confer gene-speciﬁc suppression in sequence-dependent man-
ner [27,28]. siRNAs are derived from long double-stranded
RNAs by an RNase III enzyme, identiﬁed as Dicer [29], and
one strand of the duplex is incorporated into an RNA-induced
silencing complex (RISC) [30]. The siRNA component acts as
a guide sequence, directing the complex to the target mRNA,
and then the RISC catalyzes the sequence-speciﬁc cleavage
of the target mRNA [31–33].
At least some plant miRNAs and one mouse miRNA can in-
duce cleavage of mRNAs similar to siRNA-mediated mRNA
degradation [14,22,25]. In addition, recent reports suggested
that miRNAs can induce the degradation of mRNAs when
the targets contain perfectly complementary sequences
[34,35]. Thus, miRNAs have at least two functions, transla-
tional repression and mRNA cleavage, depending on the de-
gree of complementarity of the target mRNAs. Moreover, in
a similar manner as generation of siRNAs, miRNAs are pro-
duced by the Dicer ribonuclease [11–13,29,36].
According to the recent reports, miRNAs are initially syn-
thesized as primary transcripts (pri-miRNAs) by RNA poly-
merase II (pol II), and then pri-miRNAs are processed to
precursor miRNAs (pre-miRNAs) of approximately 70 nucle-
otides (nts), each of which contains a short imperfectly base-
paired stem and a loop [37–42]. The pre-miRNA is processed
to yield miRNAs of approximately 22 nts by the Dicer [11–
13,29,36]. Although the sequence and structural requirements
for the processing of substrates by Dicer are not fully under-
stood, Dicer can speciﬁcally recognize and cleave short stems
with both perfect and imperfect base-pairs [29,36]. Therefore,
we postulated that VAI RNA might be a substrate for Dicer
since this RNA includes two short stem regions with imperfect
base-pairs within its secondary structure. Indeed, more recentblished by Elsevier B.V. All rights reserved.
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Fig. 1. Small RNAs are generated from VAI RNA. (A) Secondary structure of VAI RNA [10]. The regions complementary to probes used in
Northern blotting analysis are indicated by thick bars with diﬀerent patterns. (B) Detection of VAI RNA in cultured human cells transfected with a
control plasmid, namely pPUR, (lane C) and the VA-expressing vector (lane VA). Northern blotting analysis was performed with probes
complementary to the 5 0 region of the terminal stem (Probe 1; lanes 1–4), the 5 0 region of the apical stem (Probe 2; lanes 5–8), and the 3 0 region of the
terminal stem (Probe 3; lanes 9–12) of VAI RNA. Vertical bars indicate bands corresponding to VAI RNA, with the pattern of shading
corresponding to those in (A). A processed RNA is indicated by a black arrowhead. The duration of autoradiography was increased (lanes 3, 4, 7, 8,
11 and 12) for detection of VAI-derived small RNAs. (C) Determination of sizes of VAI-derived small RNAs. RNAs were separated on a long
denaturing 12% polyacrylamide gel in and were allowed to hybridize with Probe 3.
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ing our attempts to identify the targets of the processed VAI-
small RNA.
In the present study, we found that an imperfectly base-
paired terminal stem of VAI RNA was processed to small
RNAs of 22 nts in length in mammalian cells. Remarkably,
Dicer was involved in the processing of the terminal stem of
VAI RNA, and processed small RNAs strongly suppressed
the expression of the target gene that contained perfectly or
imperfectly complementary sequences. This evidence indicates
that the pol III non-coding transcript, VAI RNA, becomes the
source of small RNAs, acting as an miRNA and siRNA.2. Materials and methods
2.1. Construction of plasmids
For in vitro transcription of VAI RNA, we constructed plasmid
VAI/pMX-puroDDra as follows. The plasmid pMX-puroDDra was
generated from plasmid pMX-puro [44] by deleting the sequence from
positions 1883 to 3160, with removal of a DraI site. The DNA frag-
ment that included the VAI gene, the T7 promoter sequence and NotI
sites was ampliﬁed by PCR using the pAdVAntagee vector (Promega,
Madison, WI) as template and it was inserted into the NotI site of
pMX-puroDDra to yield the VAI/pMX-puroDDra. For luciferase as-
says, a 115-bp sequence containing three target repeats (positions
119–159 in the sequence of VAI) in tandem was inserted in two orien-
tations into the XbaI site of plasmid pGL3 (Promega) to generate the
pGL3-VAI-119F and pGL3-VAI-119R plasmids, as reported previ-ously [45]. To construct plasmids pGL3-VAI-1 (F and R), pGL3-
VAI-36 (F and R) and pGL3-VAI-61 (F and R), we used sequences
that contained three target repeats (positions 1–37, 36–72 and 61–97
in the sequence of VAI, respectively) in tandem, which were inserted
as described above. To construct plasmids pGL3-VAI-s135 (F and
R), we used sequence that contained the single target (positions 135–
158 in the sequence of VAI), as illustrated in Fig. 4A. To construct
plasmids pGL3-VAI-m137 (F and R) and pGL3-VAI-dm137, we used
sequence that contained four target repeats (positions 137–158 in the
sequence of VAI) with mutations, as illustrated in Fig. 4B.2.2. Culture and transfection of cells
HeLa S3, HEK 293 and NIH 3T3 cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (Sigma Chemical Co., St. Louis, MO), sup-
plemented with 10% fetal bovine serum (Life Technologies, Inc., Rock-
ville, MD) and a mixture of antibiotics (Life Technologies). Cells were
transfected with a cationic transfection reagent, TransIT-LT1 (Pan
Vera, Madison, WI), according to the manufacturer’s protocol.2.3. Northern blotting analysis
Cells were grown to approximately 80% conﬂuence (1 · 107 cells)
and transfected with the pAdVAntagee vector or the pPUR vector
(Clontech, Palo Alto, CA) using the TransIT-LT1 reagent. Twenty-
four hours later, total RNA was extracted and puriﬁed with ISO-
GENe reagent (Wako, Osaka, Japan). Fifty micrograms of total
RNA per lane were loaded on a 10% (Fig. 1B) or a 12% (Fig. 1C) poly-
acrylamide denaturing gel or a 2% an agarose gel (Fig. 5B, top). After
electrophoresis, bands of RNA were electro-transferred to a Hybond-
XLe membrane (Amersham Bioscience, Piscataway, NJ). The mem-
brane was probed with 32P-labeled synthetic oligonucleotides that were
complementary to the sequence of VAI RNA.
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The DNA fragment containing the VAI gene and the T7 promoter
sequence was ampliﬁed by PCR using the pAdVAntagee vector as
template for in vitro transcription. The VAI RNA was transcribed
with an AmpliScribee T7 transcription kit (Epicentre Technologies,
Madison, WI), according to the manufacturer’s protocol. After tran-
scription, the labeled products were separated on an 8% polyacryl-
amide/8 M urea gel and the band corresponding to VAI RNA was
excised and eluted. End-labeled VAI RNAs were incubated with HeLa
cell lysates, which were prepared by lysing cells with lysis buﬀer [10
mM Tris, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP40, 10 lg/ml
aprotinin, 10 lg/ml leupeptin, and 1 mM pefabloc SC (Roche)], at
37 C for 30 and 60 min. The products of reactions were resolved on
a 12% polyacrylamide denaturing gel. A decade marker (Ambion)
was used as the size marker for single-stranded RNA. For establish-
ment of ‘‘Dicer-knockdown’’ HeLa cells, cells were transfected with
2 lg of pPUR, and 100 nM of siRNA targeted against Dicer (sense:
5 0-GAA UCA GCC UCG CAA CAA ATT-3 0, antisense: 5 0-UUU
GUU GCG AGG CUG AUU CTT-3 0) or against ﬁreﬂy luciferase
(sense: 5 0-CUU ACG CUG AGU ACU UCG ATT-3 0, antisense:
5 0-UCG AAG UAC UCA GCG UAA GTT-3 0) (as a control) with
Lipofectaminee 2000 (Invitrogen, Carlsbad, CA) in 10-cm dishes.
Twenty-four hours after transfection, cells were treated with 2.5 lg/
ml puromycin and, after an additional incubation for 48 h, the
expression of Dicer was examined by PCR with speciﬁc-primers (sense:
5 0-TTA ACC AGC TGT GGG GAG AGG GCT G-3 0, antisense: 5 0-
AGC CAG CGA TGC AAA GAT GGT GTT G-3 0) and cDNA as
template after reverse transcription in the presence of a poly-dT primer.
2.5. S1 nuclease mapping
For preparation of the probe, the synthetic oligonuleotide 5 0-GGA
GCG CTC CCC CGT TGT CTG ACG TCG CAC ACC TGG
GTT CTT TTT TTT TT-3 0 was labeled with [c-32P]ATP by T4 poly-
nucleotide kinase (Takara Shuzo Co., Kyoto, Japan). The labeled
product was puriﬁed on a 15% polyacrylamide denaturing gel and
the band of product was excised and eluted. Total RNA was isolated
from HeLa cells that had been transfected with pAdVAntageTM or
pPUR and allowed to hybridize with the 5 0-end-labeled probe, as de-
scribed by Hahn (http://www.fhcrc.org/labs/hahn/methods/mol_bio_
meth/s1_oligo_probe.html). The reaction mixture was incubated with
S1 nuclease (Invitrogen) for 30 min at 37 C and resolved on a 15%
polyacrylamide denaturing gel.
2.6. Dicer reactions in vitro
DNA fragments encoding EBER-1 (Gene ID:16326314) or hY1
(Gene ID: 174899) were prepared by hybridizing sense and antisense
oligonucleotides. Template DNA, including 200 bp of the sequence
for EGFP, was prepared by PCR using the EGFP-N1 plasmid (Clon-
tech) with appropriate upper (5 0-TAA TAC GAC TCA CTA TAG
GGC GAG GAG CTG TTC ACC GG-3 0) and lower (5 0-TAA TAC
GAC TCA CTA TAG GGG TAG CGG CTG AAG CAC TG-3 0)
primers. RNA was transcribed in vitro in the presence of [a-32P]CTP
using the AmpliScribee T7 transcription kit. VAI RNA was also tran-
scribed from linearized VAI/pMX-puroDDra. All transcripts were
puriﬁed by electrophoresis on a 6% native polyacrylamide gel and were
incubated with a recombinant human Dicer (Gene Therapy Systems,
San Diego, CA), according to the manufacturer’s protocol. The prod-
ucts of the reactions were resolved on a 15% native polyacrylamide gel.2.7. Luciferase assays
HeLa cells were grown to approximately 50% conﬂuence in 24-well
plates and cotransfected, using the TransIT-LT1 reagent, with 0.1 lg
of a ﬁreﬂy luciferase reporter construct, 0.1 lg of a Renilla luciferase
expression vector (pRL-TK; Promega) and 0.8 lg of the VA-expres-
sion vector (pAdVAntagee) or pPUR. Forty-two hours later, lucifer-
ase activities were analyzed with a Dual Luciferase system (Promega).2.8. Viral infection
HeLa cells were infected with adenovirus mutant, Ad2/bGal-4,
which was kindly provided by Genzyme Corporation (Framingham,
MA, USA). Detection of b-galactosidase assay was detected by stain-
ing using the b-galactosidase substrate, X-gal (5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside), as described elsewhere [46].3. Results
3.1. VAI RNA is the source of small RNAs
We initially performed Northern blotting analysis to exam-
ine whether the stem regions of VAI RNA can be processed
into small RNAs of approximately 22 nts. We transfected
HeLa cells with a plasmid that encoded genes for VAI and
VAII (VA-expressing vector) and, 24 h after transfection, we
isolated RNA, fractionated it by electrophoresis, transferred
the bands of RNA to a membrane and examined their ability
to hybridize to speciﬁc probes. These probes complementary to
22-nt sequences of the stem regions of VAI yielded strong sig-
nals that corresponded to full-length VAI RNA (Fig. 1B, lanes
2, 6 and 10). Moreover, a small RNA became detectable with
increasing duration of exposure, when we used a probe, re-
ferred to as Probe 3, that was complementary to the 3 0 side
of the terminal stem of VAI (Fig. 1B, lane 12; indicated by
an arrowhead). By contrast, when we used a probe comple-
mentary to the 5 0 side of the terminal stem or to the 5 0 side
of the apical stem of VAI, no similar small RNA was detected
under these conditions (Fig. 1B, lanes 4 and 8). Similar pro-
cessing of VAI RNA occurred in HEK293 and NIH3T3 cells
(data not shown). To estimate the approximate length of the
small RNA, we repeated Northern blotting with Probe 3 after
changing the condition for electrophoresis. As shown in
Fig. 1C, we detected bands that corresponded to RNAs of
approximately 22 nts, as well as bands of other smaller and lar-
ger RNAs. Thus, the imperfectly base-paired terminal stem of
VAI RNA was cleaved in mammalian cells, with selective gen-
eration of several small RNAs from one side of the stem.
To identify the 3 0 processed fragments of VAI RNA in cul-
tured cells, we performed S1 nuclease mapping. Twenty-four
hours after transfection of HeLa cells with the VA-expressing
vector, we isolated the total RNA and incubated it with a 5 0-
end-labeled DNA probe of 50 nts that included a sequence
complementary to the 3 0 terminal stem of VAI RNA (positions
117–156) and additional 10 thymidine residues at the 3 0-end of
the DNA probe. A band of 20 nts in length was identiﬁed, in
addition to many less intense bands (Fig. 2A, lane 4, VA).
Thus, the processed major products were 20–24 nts in length
with terminal (U)n tails (n = 0–4). Although several small
RNAs of less than 20 nts in length could be generated from
the 3 0 terminal stem of the VAI RNA, it was very clear that
small RNAs of 20–24 nts were generated in cultured cells.
The exact cleavage site identiﬁed by the S1 nuclease mapping
is indicated in Fig. 2A by an arrowhead (C136).
3.2. Dicer processes VAI RNA to small RNAs
Since VAI RNA had been processed to small RNAs of 20–
24 nts by cellular factors in cultured cells, we next examined
whether Dicer might be involved in the processing of VAI
RNA. We incubated 5 0- or 3 0-end-labeled VAI RNA with ex-
tract of HeLa cells, that had been transfected with either siR-
NA against human Dicer or siRNA against ﬁreﬂy luciferase,
and then fractionated the products of reactions on a denatur-
ing polyacrylamide gel. To conﬁrm the ‘‘Dicer-knockdown’’ in
HeLa cells, we analyzed the transfected HeLa cells with a syn-
thetic siRNA against human Dicer. As shown in Fig. 2B, bot-
tom, siRNA against Dicer reduced the level of Dicer mRNA
very eﬃciently. As shown in lanes 5 and 6 of Fig. 2B, VAI
RNA was cleaved speciﬁcally immediately after U22 when
we incubated the 5 0-end-labeled VAI RNA with the extract
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Fig. 2. Processing of VAI RNA. (A) Left; S1 nuclease mapping of VAI RNA. HeLa cells were transfected with the control plasmid or the VA-
expressing plasmid. Isolated RNA was allowed to hybridize with 5 0-end-labeled DNA probe and digested by S1 nuclease. Lane 1, Size markers; lane
2, probe; lane 3, control RNA treated with S1 nuclease; lane 4, VAI-expressing RNA treated with S1 nuclease. Right; Sites of cleavage of VAI RNA.
The 5 0- and 3 0-cleavage sites in vitro are indicated by grey arrowheads. A cleavage site identiﬁed by S1 nuclease mapping is indicated by a black
arrowhead. (B) Top; Involvement of Dicer for the cleavage of VAI RNA in vitro. The 5 0- or 3 0-end-labeled VAI RNA was incubated for 30 and
60 min with extract of HeLa cells, that had been transfected with either siRNA against human Dicer or siRNA against ﬁreﬂy luciferase. Time 0*
indicates the full-length VAI RNA in the absence of cell extracts. Lane M, Size markers; lane T1, RNase T1; lane OH, an alkaline-cleavage ladder of
VAI RNA. Cleavage products are indicated by black arrowheads. The expression of Dicer was conﬁrmed by RT-PCR analysis (bottom). Results of
RT-PCR for b-actin mRNA are also shown as internal controls. (C) In vitro ‘‘dicing’’ of pol III transcripts. We incubated dsRNA of 200 nts that was
complementary to the gene for EGFP, VAI RNA, EBER-1 and hY1 RNA with recombinant Dicer. The electrophoresis for dsRNA products was
performed with non-denaturing gel, while the marker was ssRNA.
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ﬁreﬂy luciferase. When we used the 3 0-end-labeled VAI
RNA, the predominant processing sites in VAI RNA were lo-
cated immediately after A137 (Fig. 2B, lanes 13 and 14) that
was one nucleotide shorter than the previously identiﬁed
C136 site by the S1 mapping. This might reﬂect a non-natural
3 0-end of the transcribed and 3 0-end-C-labeled VAI RNA.
Importantly, no cleavage products of respective end-labeled
VAI RNAs were detected when labeled VAI RNAs were incu-
bated with the extract of ‘‘Dicer-knockdown’’ HeLa cells
(Fig. 2B, lanes 7, 8, 15 and 16). These results indicated that
VAI RNA was processed speciﬁcally by Dicer, with cleavages
in the vicinity of both sides of the terminal stem. Since we
were only able to detect small RNAs from the 3 0 side of the
terminal stem in living cells by Northern blotting (Fig. 1B
and C), it seems likely that short RNAs from the 3 0 side of
the terminal stem region might accumulate selectively in cells
after processing.
To further conﬁrm that VAI RNA can be processed by Di-
cer, we next treated VAI RNA with recombinant Dicer
in vitro. We prepared radio labeled VAI RNA and other
non-coding RNAs, namely Epstein–Barr virus-encoded RNA
(EBER-1) and human Y1 RNA (hY1). Since each of these
RNA is transcribed by RNA polymerase III in cells and con-
tains short stems within its secondary structure, each is a pos-
sible substrate for Dicer. We also prepared a double-stranded
RNA of 200 nts, which corresponded to the gene for enhanced
green ﬂuorescent protein (EGFP) (EGFP dsRNA) as a posi-
tive control, and then we incubated all the transcripts with re-
combinant Dicer. As shown in Fig. 2C, VAI RNA was
processed to small products even though the eﬃciency of the
cleavages was relatively low compared to that of the cleavage
of EGFP dsRNA. By contrast, EBER-1 RNA and hY1
RNA were not processed to small RNAs of 22–25 nts by Di-
cer. Thus, of three non-coding RNAs, only VAI RNA was a
potential substrate for Dicer. Our results conﬁrmed that VAI
RNA was speciﬁcally processed to small RNAs of approxi-
mately 22 nt by Dicer in vitro.
3.3. VAI RNA suppresses gene expression via an siRNA
pathway
After dsRNAs and pre-miRNAs have been processed to
RNAs of approximately 21–22 nts by Dicer, the processed
small RNAs (siRNAs and miRNAs) are incorporated into
RISC and they direct the complex to their target mRNAs.
To examine whether the small RNAs derived from VAI
RNA might be involved in an siRNA pathway, we used plas-
mid pGL3 to construct the reporter plasmid pGL3-VAI-119F,
which included sequences with perfect complementarity to the
3 0 terminal stem region (119–159) of VAI RNA inserted into
the 3 0 untranslated region (UTR) of the ﬁreﬂy gene for lucifer-
ase (Fig. 3A). We also constructed plasmid pGL3-VAI-119R,
which contained target sites in the reversed orientation, for
use as a control (Fig. 3A). If the small VAI-derived RNAs
were to be incorporated into RISC, they would be expected
to act as siRNAs against perfectly matched target sites, with
resultant reduction of luciferase activity by the pGL3-VAI-
119F construct. Each luciferase reporter plasmid and a plas-
mid encoding Renilla luciferase (pRL-TK) were introduced
into HeLa cells with the VA-expression vector or the pPUR
vector, and luciferase activities were determined 42 h after
transfection. When the activities of both ﬁreﬂy and Renillaluciferase in cells that harbored pPUR were set at 1 for each
reporter plasmid, it was clear that the VA-expression vector
eﬃciently enhanced the luciferase activity due to pGL3
(Fig. 3B, compare lanes 1 and 2), in accordance with earlier re-
ports that the introduction of VA RNAs into cells enhances
translational activity by blocking the activation of PKR
[7,47]. Thus, similar enhancement by VA RNAs was observed
for Renilla luciferase (compare lanes 7 and 8).
To our surprise, the VA-expression vector signiﬁcantly sup-
pressed the expression of ﬁreﬂy luciferase when cells were
cotransfected with this vector and pGL3-VAI-119F (Fig. 3B,
compare lane 6 with lanes 2 and 4), suggesting that the small
RNA detected in Fig. 1B and C did indeed act as an siRNA
against a perfect target derived from the pGL3-VAI-119F con-
struct. By contrast, the activity of ﬁreﬂy luciferase due to
pGL3-VAI-119R was enhanced by the VA-expression vector,
resembling the result for pGL3 (Fig. 3B, lane 4). The inhibi-
tory eﬀect was speciﬁc to ﬁreﬂy luciferase because the control
Renilla luciferase activities were not aﬀected by the same treat-
ment (lanes 7–12).
In addition, we conﬁrmed that the VA-expression vector
dramatically reduced the level of the expression of ﬁreﬂy
luciferase when cells were cotransfected with this vector and
pGL3-VAI-s135F, which included a single target with perfect
complementarity to the 3 0 terminal stem region (135–158) of
VAI RNA (Fig. 4A, lane 6). Thus, VAI RNA dramatically
inhibited gene expression when the target contained a sequence
that was a perfectly complementary to the 3 0 terminal stem re-
gion of VAI RNA.
Next, we examined the eﬀects of VAI RNA on a construct
that included three target sites with perfect complementarity
to nucleotides 1–37 of VAI RNA, namely, the 5 0 terminal
stem region (pGL3-VAI-1F) (Fig. 3A). In all cases, luciferase
activities were enhanced by VAI RNA (Fig. 3B; see lanes
13–24). However, it is important to note that the extent of
activation by the VAI RNA of the pGL3-VAI-1F construct
(lane 18) was signiﬁcantly lower than that of the others
(Fig. 3B; compare lane 18 with lanes 14 and 16), suggesting
the existence of limited amounts of a small RNA derived
from the 5 0 terminal stem even though our Northern blotting
analysis failed to detect such a small RNA (Fig. 1B, lane 4).
It should be emphasized, however, that the inhibitory eﬀect
of the VAI-expression vector on the activity derived from
pGL3-VAI-1F was marginal compared to that against the
activity derived from pGL3-VAI-119F (Fig. 3B; compare
lanes 6 and 18).
In addition, we examined the eﬀects of VAI RNA on con-
structs that included target sites with perfect complementarity
to nucleotides 36–72 and 61–97 of VAI RNA, namely, the api-
cal stem region (pGL3-VAI-36F and pGL3-VAI-61F, respec-
tively). In both cases, luciferase activities were strongly
enhanced by VAI RNA (Fig. 3B, lanes 30 and 42). Therefore,
the apical stem of VAI RNA could not be recognized by Dicer
and, thus, not be processed to small RNAs, although this stem
contains potential base-pairs of more than 20 nts within its sec-
ondary structure (Fig. 1A).
All these results are consistent with our conclusion based on
Northern blotting analysis. As described above, our Northern
revealed that small RNA was generated only from the 3 0 side
of the terminal stem of VAI RNA and it accumulated predom-
inantly in cells even though both strands within the terminal
stem were processed to small RNAs by Dicer in vitro.
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incorporated preferentially into the RISC, with subsequent
eﬃcient and sequence-dependent suppression of the expression
of the target reporter gene in pGL3-VAI-119F (Fig. 3B; lane
6). These results are consistent with the recent ﬁnding by
Andersson et al. [43], and we clearly demonstrated that the
small-VAI RNAs from the terminal stem, but not the apical
stem, and especially the 3 0 terminal stem of VAI had the pre-
dominant gene-suppressing activity.
3.4. VAI RNA induces translational repression via a miRNA
pathway
To examine whether the small RNAs derived from VAI
RNA might cause the gene-silencing in the miRNA pathway,
we constructed the reporter plasmid pGL3-VAI-m137F thatincluded imperfectly complementary sequences to the 3 0 termi-
nal stem region (137–158) of VAI RNA (Fig. 4B), as described
above. Because recent reports demonstrated that the ﬁrst eight
nucleotides of the 5 0 end of miRNA could correlate with the
eﬃcient translational repression [48,49], mismatches were
introduced at nucleotides 9–11 positions from the 3 0 end of
the target sequences (Fig. 4B). We also constructed two other
plasmids pGL3-VAI-m137R and pGL3-VAI-dm137, for use
as controls (Fig. 4B). The pGL3-VAI-m137R and pGL3-
VAI-dm137 contained target sites in the reversed orientation
and target sites with two more mismatches at nucleotides 4–5
positions from the 3 0 end of the target sequences, respectively.
We expected that mismatches at near the 5 0 end of miRNA
could impair the ability of VAI-derived small RNA to repress
the expression of the target gene.
1560 M. Sano et al. / FEBS Letters 580 (2006) 1553–1564When cells were cotransfected with the VA-expression vec-
tor and pGL3-VAI-m137F, the VA-expression vector signiﬁ-
cantly suppressed the expression of ﬁreﬂy luciferase whereas
the vector enhanced the activity of luciferase due to pGL3-
VAI-m137R (Fig. 4B, lanes 6 and 8). In addition, as expected,
two more mismatches at the target region completely abro-
gated the ability of VAI-derived small RNA (Fig. 4B, lane
4). Thus, the small RNA derived from the 3 0 terminal stem
of VAI can induce translational repression via the miRNA
pathway, as well as gene-silencing via an siRNA pathway.
3.5. Attempts to identify the targets of VAI-small RNA
Since the small RNAs derived from VAI RNA caused the
gene-silencing of the reporter plasmid pGL3-VAI-m137F that
included imperfectly complementary sequences to the 3 0 ter-
minal stem region (137–158) of VAI RNA, the VAI-small
RNAs might regulate cellular genes as miRNAs. We thus
used a computational method in an attempt to identify po-
tential targets for the VAI-derived small RNAs. Although
we failed to identify any cellular targets with perfect comple-
mentarity to VAI RNA, we did identify several potential tar-
gets, including the gene for Dicer (Supplemental Table 1). In
addition to Dicer, we predicted several potential targets,
including an apoptosis-related gene (NAPOR), and genes
for kinases (PAK2 and PIP5K1C), which contain imperfect
complementary sequences within their 3 0 UTR (Supplemental
Table 1). To conﬁrm the potential target sites of candidate
mRNAs, we made several reporter constructs consisting of
the gene for luciferase fused with the predicted potential tar-
get sequence(s) (Supplemental Table 1), the reporter con-
struct corresponding to the one shown in Fig. 4B. The
reporter constructs included PKR-activating protein (PACT).
Since PACT is an important mediator of cellular defense sys-
tems, VAI-small RNAs might help adenoviruses to circum-
vent cellular defense systems, together with the parental
VAI RNA, by blocking the activation of PKR, as schemati-
cally illustrated in Supplemental Fig. 1.
Each luciferase reporter plasmid and a plasmid encoding Re-
nilla luciferase (pRL-TK) were introduced into HeLa cells with
the VA-expression vector or the pPUR vector, and luciferase
activities were determined 42 h after transfection. In almost
all cases, VAI RNA could not suppress the reporter activity.
However, we observed reduction of reporter activity when
we cotransfected cells with the VA-expression vector and a re-
porter construct that included four tandem repeats with the
predicted short target sequence, 5 0-GAG AAG UGC GCC
AAU GUU GUC U-3 0, of Dicer (Supplemental Fig. 2A).
Thus, we attached a partial UTR sequence (1.3 kb), which
contained the predicted target sequence, of Dicer to the repor-
ter gene and measured the luciferase activity. However, VA-
expression vector could not reduce the reporter activity of
the construct with the partial UTR (Supplemental Fig. 2B).
More detailed analyses are required to identify the real target
of VAI-derived miRNA.
3.6. Gene suppression by VAI RNA during adenoviral infection
To further ask whether VAI RNA might inhibit gene-
expression via siRNA and miRNA pathways during adeno-
viral infection, we attempted to use adenovirus mutant with
replacement of the early region 1 coding genes, E1A and
E1B, by the gene for b-galactosidase [50,51]. Since E1A
and E1B proteins are essential for the eﬃcient viral replica-tion, this adenovirus mutant is replication incompetent.
However, this virus can eﬃciently infect a broad range of
cell lines.
To initially examine the eﬃciency of the viral infection, we
infected HeLa cells with various titers of the adenovirus mu-
tant, and assayed for b-galactosidase 42 h after infection.
Although 5.5 · 108 units/ml of the virus showed the highest le-
vel of infection, the virus in this condition impaired the rate of
cell growth. Therefore, for further studies, we decided to use
2 · 107 units/ml of the virus, which conferred approximately
70% eﬃciency of infection (Fig. 5A).
We next investigated the expression of VAI RNA during vir-
al infection using infected HeLa cells. Northern blotting anal-
ysis revealed that VAI RNA was detectable 8 h after infection,
and levels of expression were gradually increased until 32 h
after infection even if the expression level of VAI was much
lower than that due to VAI-expression vector (Fig. 5B, top).
Moreover, approximately 22 nts of small RNAs became
detectable 24 h after infection, when we used the probe that
was complementary to the 3 0 side of the terminal stem of
VAI, as indicated in Fig. 1A (Fig. 5B, bottom, indicated by
an arrowhead).
To examine the eﬀect of viral infection on the plasmid
pGL3-VAI-s135F that included a single target site with perfect
complementarity to 3 0 side of the terminal stem of VAI, as
illustrated in Fig. 4A, HeLa cells were cotransfected with
pGL3-VAI-s135F and pRL-TK, and infected the cells with
the virus 6 h after transfection, and luciferase activities were
determined further 42 h after infection. When the relative lucif-
erase activities in cells with no viral infection were set at 100%
for the reporter plasmid, it was clear that the virus eﬃciently
inhibited the luciferase activity due to pGL3-VAI-s135F
(Fig. 5C, lane 6). In contrast, the virus slightly enhanced the
activity of ﬁreﬂy luciferase due to both pGL3 and pGL3-
VAI-s135R, which included the target in the reversed orienta-
tion (Fig. 5C, lanes 2 and 4). Based on the reporter assay by
using VAI-expressing vector, VAI RNA can strongly suppress
gene-expression when a target contains perfectly matched se-
quence, whereas VAI can increase the level of expression of re-
porter genes with unrelated targets.
We next examined whether viral infection could have some
eﬀects on the construct pGL3-VAI-m137F, which included
imperfectly matched targets, as illustrated in Fig. 4B. As
shown in Fig. 5C, bottom, the luciferase activity due to
pGL3-VAI-m137F was dramatically suppressed during viral
infection (compare lane 14 with lanes 8, 10, 12). Importantly,
the virus enhanced the luciferase activity due to pGL3-VAI-
dm137, which included target sites with additional mismatches
at the 5 0 region of VAI-derived small RNA. Thus, these results
apparently indicate that VAI RNA can be processed to small
RNAs during viral infection, and resultant products can act
as not only siRNA but also miRNA against both perfectly
and imperfectly matched targets.4. Discussion
Adenoviruses have evolved several strategies that allow them
to counteract cellular defense systems. For example, the virus-
encoded pol-III transcripts VAI and VAII RNAs play an
important role in eﬃcient viral replication. In this study, we
demonstrated that small RNAs derived from VAI RNA can
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accordance with the recent ﬁndings by Andersson et al. [43].
Our analysis revealed that the 3 0 terminal stem region of
VAI RNA was indeed processed to small RNAs (Figs. 1 and
2A). Dicer was involved in the processing of VAI RNA
(Fig. 2B and C), and subsequently small RNAs derived from
the 3 0 stem of VAI were preferentially incorporated into RISC
to inhibit the expression of genes that included sequences com-
plementary to VAI RNA (Fig. 3). Further analysis demon-
strated that VAI-derived small RNA can act as miRNA
because the VAI-small RNA could suppress gene-expression
even if the targets contained mismatches at the center of thetarget region (Fig. 4B, lane 8). However, mismatches near
the 5 0 end of the small RNA completely abrogated transla-
tional suppression (Fig. 4B, lane 4), as reported by other
groups [48,49]. We demonstrated that the pol-III transcript,
VAI RNA, can be a substrate for Dicer, and the resultant
small RNAs derived from the 3 0 terminal stem of VAI RNA
can act as siRNA and miRNA. Our results suggested that
other pol III-transcribed non-coding RNAs might be sub-
strates for Dicer, and diced products might regulate cellular
phenomena although two non-coding RNAs, EBER-1 and
hY1, could not produce 22 nts small RNAs by the Dicer
in vitro.
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is thought to be the main polymerase for miRNA transcription
[39,40], except in the case of recently identiﬁed mouse gamma-
herpesvirus 68 (MHV68)-derived miRNAs that are produced
from pol III tRNA promoter [52]. Our data suggested that
some potential miRNAs were derived from pol III transcript.
It is possible that some of pol III non-coding RNAs with stable
stem structures might be precursors for producing siRNAs and
miRNAs. In fact, we found that small RNAs are generated in
cultured cells from the 3 0 terminal stem of VAII RNA and that
they promote sequence-dependent gene-silencing during viral
infection (Supplemental Fig. 3), as also reported by Andersson
et al. [43]. Thus, small RNAs derived from pol III transcripts
might act similarly to siRNA and miRNA in vivo. However,
it should be noted that VAI and VAII RNA have to use the
Exportin 5-mediated nuclear export pathway, which recog-
nizes small RNAs containing a terminal stem and a short 3 0
overhang, i.e., essentially perfect substrate for Dicer cleavage
[54,55], so that the ineﬃcient production of a low level of
VAI-small RNAs may be a function of the similarity of the se-
quence requirements of Exportin 5 and Dicer and, hence, phys-
iological relevance needs to be further examined.
Tuschl and coworkers identiﬁed several genes for miRNAs
in the genome of Epstein–Barr virus (EBV) and they used a
computational method to predict targets for EBV miRNAs
[53]. Recently, other viral miRNAs have been identiﬁed from
Kaposi sarcoma-associated virus, human cytomegalovirus,
simian virus 40 and others [52,56,57]. Computational predic-
tions allowed them to identify several host-cell and viral encod-
ing targets for viral miRNAs. Viral miRNAs are probably
involved in the regulation of many cellular phenomena associ-
ated with viral replication. Importantly, our results demon-
strated that sequence-speciﬁc gene suppression by VAI RNA
occurred during adenoviral infection (Fig. 5C). This result al-
lows the hypothesis that VAI-small RNAs might regulate cel-
lular phenomena similarly to miRNA and siRNA, although
our attempts to identify the exact targets were not successful
(Supplemental Table 1, Supplemental Figs. 1 and 2). Unfortu-
nately, all our reporter constructs for the potential targets,
including Dicer, did not show signiﬁcant suppression by the
VAI-small RNAs when each target gene was examined individ-
ually. It should be mentioned, however, that we cannot exclude
the possibility that the VAI-small RNAs might simultaneously
target multiple genes, including e.g. Dicer, and only the syner-
getic eﬀects might regulate cellular phenomena. More detailed
analyses are required to identify the real target of VAI-derived
miRNA.
Adenovirus VAI RNA can help adenoviruses to circumvent
cellular defense systems by blocking the activation of PKR.
Recently, Lu and Cullen have reported that VAI RNA could
also inhibit RNAi and the biogenesis of both miRNA and siR-
NA through the inhibition of nuclear export of pre-miRNA
and shRNA, and inhibition of the function of Dicer by binding
to Dicer [55]. They suggested that VAI RNA might counteract
cellular defense systems against adenovirus by attenuating any
RNAi responses to viral infection, as seen in some plant
viruses [58]. Moreover, Akusja¨rvi and coworkers have also re-
ported that adenovirus VAI and VAII RNAs (VA RNAs)
have capacity to suppress RNAi by blocking Dicer and RISC
functions [43]. They provided evidence that extracts prepared
from cells at late stages of adenoviral infection suppressed Di-
cer activity in vitro, and that VA RNAs were processed intosmall RNAs during lytic infection. Moreover, in vitro diced-
VA RNAs suppressed the expression of luciferase from repor-
ter plasmids that contain partial sequences of VA RNAs. They
suggested that the terminal stem of VA RNAs could be incor-
porated into RISC.
Our present data are consistent with their observation. How-
ever, we further determined the possible processing sites of
VAI RNA and conﬁrmed that the processed small RNA can
act as miRNAs or as siRNAs in transient transfection assays
and during viral infection. Indeed, the VAI RNA dramatically
reduced the level of the expression of reporter luciferase from
pGL3-VAI-s135F, which included a short single target with
perfect complementarity to the 3 0 terminal stem region (135–
158) of VAI RNA (Fig. 4A). In addition, VAI-derived small
RNA can suppress gene-expression even if the target contains
mismatches at the center of the target region (Fig. 4B). A
quantitative analysis estimated that the processing eﬃciency
of VAI was approximately 0.7% during wild-type adenoviral
infection (calculated from the results shown in Supplemental
Fig. 4). Since the high copies of VAI RNA are expressed at late
times of an adenovirus infection (up to 108 copies/cell), the
processed small RNA can act to repress the level of the target
expression as miRNAs because more than 105 copies of small
RNAs can be produced in the cell.
Multiple functions of VAI RNA probably are essential for
eﬃcient replication during viral life cycle. We demonstrate that
small RNAs derived from VAI RNA can indeed suppress gene
expression in a sequence-dependent manner. Therefore, it
seems possible that such small RNAs are able to regulate the
phenomena that are involved in cellular defense systems and
help adenoviruses to escape the action of the defense systems.
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